Help us: Donate
Follow us on:
×

Menu

Back

Cellvie Raises $5 Million to Develop Mitochondrial Therapeutics

Kizoo leads the way in $5 million seed funding round

Cellvie's corporate logoCellvie's corporate logo
 

https://cellvie.bio/The mitochondria are an important target in aging, as their age-related dysfunction is thought to be a reason we age. These tiny power stations living in our cells do a wonderful job producing energy and keeping us alive, but, as we age, they become increasingly dysfunctional and that supports the onset of various age-related diseases.

Today, we were delighted to learn that Cellvie has just closed a $5 million seed round to begin developing rejuvenation biotechnology that seeks to address mitochondrial dysfunction.

I asked Dr. Alexander Schueller (one of the founders and CEO of Cellvie) for a quote, and he sent the following:

With mitochondrial dysfunction or the loss of mitochondria mass associated with a variety of aging-related ailments, we are hopeful that therapeutic mitochondria transfer can emerge as a new treatment modality in this field. Particularly since the approach is fundamentally different from past attempts to treat cells’ energy metabolism. TMT acts through augmentation and replacement by introducing viable, healthy mitochondria, rather than seeking to drug endogenous mitochondria.

The official press release is as follows:

Berlin/Zurich and Houston. Harvard spin-off Cellvie Inc. closes its $5M seed round led by Kizoo Technology Capital to advance its product pipeline, including a first application in rejuvenation.

Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinson’s and Alzheimer’s, over heart attacks and strokes, to age-related degeneration.

“But treating mitochondria has proven to be an arduous challenge” said Dr. James McCully, a founder of Cellvie and Associate Professor of Surgery at Boston’s Children’s Hospital and Harvard Medical School where he pioneered the therapeutic use of mitochondria. “That is why we turned to introducing healthy, viable mitochondria into cells where these organelles are impaired. To great effect. We can sustainably reinvigorate cells’ failing energy metabolism.”

The potential of Therapeutic Mitochondria Transfer was recently demonstrated in a clinical investigation at Boston Children’s Hospital. Pediatric patients on heart-lung-support after suffering a cardiogenic shock, received the treatment to revitalize their heart muscle. 80% of these children experienced myocardial recovery, which compares to an expected 29%, as reported in a publication forthcoming in The Journal of Thoracic and Cardiovascular Surgery.

“The implications of our findings are groundbreaking. We may have the chance to bring about a new treatment modality,” said Dr. Alexander Schueller, founder and CEO of Cellvie. “The investment will enable us to pursue the platform broadly, including a first application in aging, where the need for mitochondria-recovery is particularly dear.”

​To date, Cellvie focused primarily on ischemia-reperfusion injury (IRI), one of the world’s leading causes of death. IRI manifests itself whenever the blood flow to a part of the body is interrupted and subsequently reintroduced. Well-known medical conditions include heart attacks, strokes, and organ transplantation. cellvie is pursuing an indication in organ transplantation, first, for which the FDA awarded orphan drug designation in 2020. The capital injection will be employed for productization, to expand cellvie’s product pipeline and to prepare an IND submission for a clinical study in kidney transplantation.

​“We were immediately attracted to the potential of Cellvie’s approach to emerge as a novel category of medicines” said Frank Schueler, Managing Director at Kizoo Technology Capital. “With mitochondria dysfunction a common denominator to disease and aging alike, cellvie’s ability to affect the cell energy metabolism may pave the road to address hitherto intractable human ailments”. Frank Schueler will join the company’s Board of Directors.

About Cellvie Inc

Founded in the US and headquartered close to Zürich, Switzerland, cellvieis developing medicinesfrom cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond.​

About Kizoo

KIZOO provides mentoring, seed and early-stage financing with a focus on rejuvenation biotech. Having been entrepreneurs, VC, and mentors in both high growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech – a young industry that will eventually outgrow today’s largest technology markets.

​As part of the Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elevian, Oisin Biotechnologies, LIfT BioSiences, MAIA Biotechnology, FoxBio, Turn.bio, and others.

Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

Further information can be found at www.kizoo.com and www.forever-healthy.org.

Source: Forever Healthy

HELP SPREAD THE WORD
Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension:
Lifespan.io YouTube
Lifespan.io Facebook
Lifespan.io Twitter
Lifespan.io Instagram
Lifespan.io Instagram
Lifespan.io Discord
Thank You!

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.